KINGSEY FALLS, QC (News release) -- Cascades Inc. reports its unaudited financial results for the three-month period ended March 31, 2025.
Q1 2025 Highlights
-
Sales of $1,154 million (compared with $1,211 million in Q4 2024 and $1,109 million in Q1 2024);
-
Operating income of $50 million (compared with $16 million in Q4 2024 and $9 million in Q1 2024);
-
Net earnings per common share of $0.07 (compared with a net loss per common share of ($0.13) in Q4 2024 and a net loss per common share of ($0.20) in Q1 2024);
-
Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA (A)1) of $125 million (compared with $146 million in Q4 2024 and $103 million in Q1 2024);
-
Adjusted net earnings per common share1 of $0.13 (compared with adjusted net earnings per common share1 of $0.25 in Q4 2024 and adjusted net loss per common share1 $0.00 in Q1 2024);
-
Net debt1 of $2,216 million as of March 31, 2025 (compared with $2,096 million as of December 31, 2024). Net debt to EBITDA (A) ratio1 of 4.2x, unchanged from December 31, 2024;
-
Total capital expenditures, net of disposals, totaled $36 million in Q1 2025, compared to $29 million in Q4 2024 and $41 million in Q1 2024. The Corporation's 2025 forecasted capital expenditures before disposals will be approximately $175 million.
Discussing near-term outlook, Mr. Simon commented, "We are expecting stronger second quarter results. The sequential improvement in packaging will reflect benefits from the implementation of previously announced price increases. We expect improved tissue performance to be driven by volume growth, with positive retail tissue trends and a pick up in Away-from-Home, along with pricing initiatives, the benefits of which are expected to mitigate higher raw material costs. Broadly, continued uncertainty in the macro-economic environment may impact future demand levels across North America and our outlook."